Introduction:
Aurigene Pharmaceutical Services Limited, a subsidiary of Dr. Reddy's Laboratories, invests $40 million to construct a new development and manufacturing facility.
Features:
Aurigene Pharmaceutical Services Limited is an R&D and pilot scale facility at Genome Valley, a renowned Biotechnology Park in Hyderabad.
The facility aims to meet the process development and clinical supply needs of global biotech companies.
It is designed with a state-of-the-art concept, providing maximum flexibility for a multi-product, multi-platform offering in therapeutic proteins, antibodies, and viral vectors.
The facility offers end-to-end and high-quality services for antibodies, proteins, and viral vectors.
The expansion provides global customers with access to a dedicated team, modern labs, including a pilot facility.
Exclusive access is granted to an established large-scale GMP manufacturing facility with a drug substance capacity of 15kl and fill-finish capabilities, enabling the seamless provision of commercial quantities.
The facility is planned to be fully operational in the first half of 2024.
Specifications:
Name: Aurigene Pharmaceutical Services Limited
Type: Expansion
Year: 2024
